55 posters,  8 sessions,  14 topics,  53 authors,  38 institutions
ePostersLive® by SciGen® Technologies S.A. All rights reserved.

PM07
Cost-Effectiveness of CPX-351 Versus 7+3 Regimen in the Treatment of Treatment-related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-related Changes (MRC)

Poster Presenter
Affiliations

Rate

No votes yet

Cost-Effectiveness of CPX-351 Versus 7+3 Regimen in the Treatment of Treatment-related

Acute Myeloid Leukemia (tAML) or AML With Myelodysplasia-related Changes (AML-MRC)

Anuraag Kansal, Oscar Herrera-Restrepo, Robert Leipold, Robert J. Ryan, Arthur C. Louie, Karen C. Chung

Evidera, Bethesda, MD, USA; Jazz Pharmaceuticals, Inc., Palo Alto, CA, USA.

 

Poster PM07

 

Background

• CPX-351, a novel synergistic fixed 5:1 molar ratio cytarabine:daunorubicin formulation,

is US FDA-approved for adults with newly diagnosed treatment-related acute myeloid

leukemia (tAML) or AML with myelodysplasia-related changes (AML-MRC), based on an

overall survival (OS) improvement in a phase 3 trial (NCT01696084)

• In the phase 3 trial comparing CPX-351 with the conventional 7+3 regimen (1-2 induction

cycles; up to 2 consolidation cycles)1:

––Median OS was 9.56 months with CPX-351 versus 5.95 months with 7+3,

a 31% reduction in risk of death (hazard ratio = 0.69; 1-sided P = 0.003)

–– The overall remission rate (complete remission + complete remission with incomplete

neutrophil or platelet recovery [CR+CRi]) was greater with CPX-351 (48%) versus 7+3 (33%)

(2-sided P = 0.016)

––More patients in the CPX-351 arm (34%) received hematopoietic cell transplantation

(HCT) compared with the 7+3 arm (25%; 2-sided P = 0.098)

• Administration of CPX-351 for the first induction is substantially different from the

7+3 regimen

–– CPX-351: 90-minute intravenous (IV) infusion on Days 1, 3, and 5

–– 7+3: separately administered cytarabine (24-hour continuous IV infusion on Days 1-7)

and daunorubicin (15- to 30-minute IV infusion on Days 1, 2, and 3)

 

Conclusions

• Analyses suggest CPX-351 is a cost-effective option for the treatment

of newly diagnosed tAML and AML-MRC compared with the 7+3 standard

of care in the United States

• CPX-351 resulted in higher costs (driven by higher treatment costs during

the induction and consolidation phases and HCT) than the 7+3 regimen,

but it had superior results in terms of patient survival and health-related

quality of life

Enter Poster ID (e.gGoNextPreviousCurrent